- 作者：Kathrin Kirchheiner ; MSc ; PhD&lowast ; ; kathrin.kirchheiner@meduniwien.ac.at" class="auth_mail" title="E-mail the corresponding author ; Richard Pö ; tter ; MD&lowast ; ; &dagger ; ; Kari Tanderup ; PhD&Dagger ; ; Jacob C. Lindegaard ; MD ; DMSc&Dagger ; ; Christine Haie-Meder ; MD§ ; ; Primož Petrič ; MSc ; MD‖ ; ¶ ; ; Umesh Mahantshetty ; DMRT ; MD ; DNB# ; Ina M. Jü ; rgenliemk-Schulz ; MD ; PhD&lowast ; &lowast ; ; Bhavana Rai ; MD ; DNB&dagger ; &dagger ; ; Rachel Cooper ; FRCR&Dagger ; &Dagger ; ; Wolfgang Dö ; rr ; DVM ; PhD&lowast ; ; &dagger ; ; Remi A. Nout ; MD ; PhD§ ; § ; ; for the EMBRACE Collaborative GroupJacob Lindegaard ; Kari Tanderup ; Lars Fokdal ; Elzbieta Van Der Steen Banasik ; Christine Haie-Meder ; Isabelle Dumas ; Cyrus Chargari ; Remi A. Nout ; Erik Van Limbergen ; Primož Petrič ; Barbara Segedin ; Robert Hudej ; Beth Erickson ; Peter Hoskin ; Gerry Lowe ; Umesh Mahantshetty ; Jamema Swamidas ; Shyam Kishore Shrivastava ; Ina M. Jü ; rgenliemk-Schulz ; Astrid De Leeuw ; Kathrin Kirchheiner ; Wolfgang Dö ; rr ; Richard Pö ; tter ; Ludy C.H.W. Lutgens ; Janaki Hadjiev ; Rachel Cooper ; Peter Bownes ; Marit Sundset ; Kjersti Bruheim ; Taran Paulsen Hellebust ; Fleur Huang ; Geetha Menon ; Elena Villafranca ; Bhavana Rai ; Arun S. Oinam ; Li Tee Tan ; Francois Bachand ; Geraldine Jacobson ; Maarit Anttila ; Bradley Pieters
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2016
- 出版时间：1 April 2016
- 年：2016
- 卷：94
- 期：5
- 页码：1088-1098
- 全文大小：928 K
Methods and Materials
In total, 744 patients at a median follow-up of 21 months were included. QoL was prospectively assessed using European Organization for Research and Treatment of Cancer Quality of Life core module 30 (EORTC QLQ-C30) and EORTC cervical cancer module 24 (CX24) questionnaires at baseline, then every 3 months during the first year, every 6 months in the second and third years, and finally yearly thereafter in patients with no evidence of disease. Outcomes were evaluated over time and compared to those from an age-matched female reference population.
Results
General QoL and emotional and social functioning were impaired at baseline but improved during the first 6 months after treatment, to reach a level comparable to that of the reference population, whereas cognitive functioning remained impaired. Both social and role functioning showed the lowest scores at baseline but which increased after treatment to reach a plateau at 6 months and then declined slightly at 3 and 4 years. The overall symptom experience was elevated at baseline and decreased to a level within the range of that of the reference population. Similarly, tumor-related symptoms (eg, pain, appetite loss, and constipation), which were present before treatment, decreased substantially at the first follow-up after treatment. Several treatment-related symptoms developed either immediately after and persisted over time (diarrhea, menopausal symptoms, peripheral neuropathy, and sexual functioning problems) or developed gradually after treatment (lymphedema and dyspnea).
Conclusions
This longitudinal prospective QoL analysis showed that patients' general QoL and functioning were impaired before treatment compared to those of reference data. Several tumor-related symptoms resolved after treatment, and functioning and general QoL returned to that of the level of the reference population, indicating a transient impact of diagnosis and treatment. However, several treatment-related symptoms and problems did develop and persist, either immediately or gradually after treatment.